Egetis Therapeutics is a publicly traded company on Nasdaq Stockholm. The firm recently strengthened its balance sheet through an oversubscribed directed share issue that brought in approximately SEK 183 million before transaction costs. In the transaction, the company issued 35,923,812 new common shares at a subscription price of SEK 5.10 per share, reflecting a 4.9 percent discount to the closing price on 2 October 2025. The capital raise attracted both Swedish and international investors, including Frazier Life Sciences, Invus, Petrichor, Woodline Partners LP, Fjärde AP-fonden and Linc AB. Proceeds from the financing increase the company’s financial flexibility for its ongoing corporate activities. The oversubscription signals strong market confidence in the company and its future prospects.

Total raised

$19M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2025